3. prof. dr. agnes_ecmo final
DESCRIPTION
ECMOTRANSCRIPT
![Page 1: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/1.jpg)
Dr Agnes Ng
KK Women’s and Children’s Hospital
Singapore
![Page 2: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/2.jpg)
Overview
History
Current status & outcomes
Medical simulation
![Page 3: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/3.jpg)
Extracorporeal life support ECLS
Use of modified CPB circuit to provide prolonged cardiopulmonary support
![Page 4: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/4.jpg)
In patients with respiratory and/or cardiac failure
-Failing to respond to maximal medical therapy
-Inability to wean off CPB
![Page 5: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/5.jpg)
Allows for evaluation, diagnosis & treatment Recovery from primary injury and disease
Bridge to definitive therapy
![Page 6: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/6.jpg)
Partial or full temporary support
Controls gas exchange and perfusion
Stabilises patient physiologically
![Page 7: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/7.jpg)
VA cannulation drains blood from vena cava and returns it through a major artery, aorta carotid (in children) or femoral artery
![Page 8: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/8.jpg)
VA ECMO complications Vascular trauma Systemic thromboembolisation Ischemia (arterial ischemia of extremities) Retrograde flow of oxygenated blood via aorta may not reach proximal circulation i.e. coronaries and cerebral arteries
![Page 9: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/9.jpg)
VV access puts the artificial lung in series with the native lung Preferred in respiratory failure as normal haemodynamics are maintained and there’s little risk of systemic embolism
•Avoids major artery trauma •Provides direct pulmonary oxygenation •Improves coronary oxygenation •Limits neurological Cx •Maintains patient pulsatility and CO •Vasopressors not contraindication
![Page 10: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/10.jpg)
Anticoagulation
Respiratory
Cardiovascular
Neurology
Renal
Gastro-intestinal
Haematology
Skin care
Infection
![Page 11: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/11.jpg)
Bleeding 10-30%
Technical failure e.g. failure of membrane lung or pump <5%
Cannulation complications e.g. site bleeding, perforation, tamponade, arrhythmias, distal ischemia
Systemic air or thromboembolism
Infection
![Page 12: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/12.jpg)
Historical perspective
![Page 13: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/13.jpg)
1930s Gibbon discovered heart lung machine
1950s Use in cardiac surgery
Duration limited by direct air-blood interface, activates blood components
1960s Kolobow; Silicone membrane oxygenators allowed long term support
Bartlett & Drinker; heparin titration & ACT measurement
Thrombocytopenia Hemolysis Coagulopathy Generalised edema Multiple organ failure
![Page 14: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/14.jpg)
Described partial VA ECMO for young man who developed “shock lung” syndrome following polytrauma injuries
including ruptured aorta
Hill et al NEJM 1972;286-634
![Page 15: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/15.jpg)
Esperanza (Hope) 1975 First ECMO baby
Photograph from Robert Bartlett
![Page 16: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/16.jpg)
Most successful in
newborns with life-threatening pulmonary failure
Unlike adults 10% survival
1985: Bartlett Extracorporeal Circulation in NN Respiratory Failure Pediatrics; 76;479
![Page 17: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/17.jpg)
Dramatic success in NB
(75%)
Reversible disease
PPH with PFC
ECMO started earlier
Neonatal lungs inherently
more capable of repair
& regeneration
High mortality in adults
(90%)
Severe parenchymal disease
Last resort with iatrogenic lung damage
![Page 18: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/18.jpg)
Paved the way for older children and adults for respiratory and cardiac support
![Page 19: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/19.jpg)
Major lesson learnt was the value of “lung rest” through the use of ECLS
Allows lungs to heal preventing the damage by ventilator therapy and oxygen toxicity
ECMO is ineffective as lung damages increases
![Page 20: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/20.jpg)
Started as study group contributing to a registry of cases in 1980
Established in 1989
Foster research, collaboration and practice guidelines among centers performing ECLS.
Surgeons, neonatologists, nurses, perfusionists, respiratory therapists, biomedical engineers
![Page 21: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/21.jpg)
Shared knowledge –ELSO
Improved understanding of physiology of ECMO
![Page 22: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/22.jpg)
Dedicated ECLS specialists
ECLS-trained bedside nurses
Routine ICU procedure
![Page 23: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/23.jpg)
New ECMO devices; membrane lungs and vascular devices
Pumps: low resistance & highly reliable pumps
Oxygenators: lower pressures, efficient & low resistance polymethylpentene
Double-lumen venous cannulae
![Page 24: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/24.jpg)
Avalon Elite™ Bi‐Caval Dual Lumen
![Page 25: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/25.jpg)
Current status
![Page 26: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/26.jpg)
Decline as less invasive therapies emerge;
High Frequency Oscillation, exogenous surfactant, inhalational nitric oxide, permissive hypercapnia
Meconium aspiration Congenital Diaphragmatic Hernia Persistent Pulmonary Hypertension Hyaline Membrane Disease Sepsis
![Page 27: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/27.jpg)
![Page 28: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/28.jpg)
99% Cardiac
Respiratory
1% 1%
79%
20% Other
VA
VV
ELSO Registry Jan 2011 28004 neonates
![Page 29: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/29.jpg)
![Page 30: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/30.jpg)
Wide range of causes from infection to trauma
Main indication is failure to respond to optimal ventilator and systemic management
![Page 31: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/31.jpg)
runs % surv
Viral Pn 989 63
Bac Pn 533 57
Aspiration 205 66
ARDS 523 55
ARF 817 51
Others 1791 52
Increasing use of VV ECLS Preserved carotid artery, less risk of arterial emboli Normal coronary, cerebral and pulmonary blood flow, decreases PVR
![Page 32: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/32.jpg)
Retrospective review 1993-2007 3213 children 1 month-18 yrs Overall survival 57% Wide variation: 83% status asthmaticus to 39% pertussis Decreased survival; renal failure (33%), liver failure (19%) hemapoietic stem cell tranpl (5%), ventilation>2 weeks Increasing proportion of patients with co-morbidities offered ECMO
![Page 33: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/33.jpg)
1972: First successful ECMO in adult
1979: Zapol ECMO in ARDS trial was stopped due to futility
2004-2007: UK trial 76% vs 50% survival
2009: H1N1 worldwide f lu epidemic renewed interest in ECMO
![Page 34: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/34.jpg)
Multicentre RCT 180 adults 18-65 years Severe but potentially reversible respiratory failure Murray >3 or pH<7.2 Excluded high PIP or high FiO2, ventilation>7 days, contraindication to heparin 1:1 continued conventional management or referral to single centre for consideration of ECMO Primary outcome: death or severe disability at 6 months
Peek et al Lancet 2009 ,374: 1351-1363
![Page 35: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/35.jpg)
Results 180 adults 75% (68/90) actually received ECMO 63% (57/90) vs 47% (41/87) survived 6 months without disability RR 0.69; 95%CI 0.05-0.97 (p=0.03) Mortality 37% vs 45% NS Trial was stopped for efficacy Authors recommend
Transferring patients with severe but potentially reversible respiratory failure to centres with ECMO based management protocol to improve survival without disability
![Page 36: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/36.jpg)
Observational study June 1 to Aug 31 ANZ ECMO investigators
• 68/201 patients with confirmed or suspected H1N1
received ECMO after failure on conventional therapy
• 38 initiated ECMO at referring centre and transferred to tertiary care centre
• Median time on ventilator 2 days before ECMO
• Median ECMO duration 10 days
• VV 93% vs VA 7%
Davis et al JAMA 2009:374; 1888-95
![Page 37: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/37.jpg)
71% survived to ICU discharge, 47% home
21% mortality at end of study ( 6 still in ICU)
ECMO patients often young adults with severe hypoxemia
Davis et al JAMA 2009:374; 1888-95
![Page 38: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/38.jpg)
ARDS & Septic Shock – indication for ECMO
![Page 39: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/39.jpg)
Physiologic response in sepsis varies with age
Primary response in
NB: PVR severe hypoxemia, PPH & RVF
Infants & younger children: LVF and low CO
Older child: distributive shock and high CO
ECMO improves survival in both neonatal and pediatric population resistant to fluid and catecholamine therapy
![Page 40: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/40.jpg)
70
37 29
83
54
43
0
20
40
60
80
100
Neonates Children Adolescents
VA
VV
Skinner et al J Ped Surg 2012 47:63-67
N=2669 N=232 N=34
![Page 41: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/41.jpg)
Haemodynamic response is complex
Deaths:
Refractory hypotension & distributive shock
Progressive ventricle dilation & cardiogenic shock
Multi-organ failure
May have a role in severe sepsis where hypoxemia or inadequate cardiac output
![Page 42: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/42.jpg)
Children – myocarditis and cardiomyopathy
Adults – cardiogenic shock following AMI, myocarditis & cardiomyopathy
![Page 43: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/43.jpg)
Bridge to recovery, intervention (revascularisation)
cardiac assist device or transplant
![Page 44: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/44.jpg)
NB & Ped % survival Adults % survival
Congenital defect 7227 41 144 36
Cardiac arrest 221 37 84 27
Cardiogenic shock 177 43 196 39
Myocardiopathy 626 60 223 45
Myocarditis 306 65 64 69
Others 1268 47 1015 37
![Page 45: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/45.jpg)
![Page 46: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/46.jpg)
Provides cardiopulmonary support during in-hospital cardiac arrest refractory to CPR
Cause of arrest is reversible or amenable to transplant
Requires a primed circuit and a cannulation team readily available
![Page 47: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/47.jpg)
Retrospective study from ELSO registry
297 patients >18 years, 1992-2007
75% had cardiac disease
27% survival to discharge
acute viral myocarditis, higher pre-ECMO PaO2 and percutaneous cannulation and absence of ECMO complications
No data of short or long term neurological outcome
Thiagarajan et al Ann Thorac Surg 2009;87:778-85
![Page 48: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/48.jpg)
ELSO registry
682 patients (1992-2005)
38% survival
-Neonatal respiratory disease and cardiac disease
-Absence of severe metabolic acidoisis pre ECMO
-Uncomplicated ECMO course
Thiagarajan Circulation 2007;116:1639-1700
![Page 49: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/49.jpg)
199 /5096 of CPA who received E-CPR
98% had witnessed CPA events
VF/pulseless VT vs Asystole/PEA 54% vs 34%
44% (87) survived to discharge
64% (56) had favourable neurological outcome
Pre-existing cardiac-medical/surgical had improved odds of surviving discharge
Tia et al Pediatr \ Care Med 2010 11:3
![Page 50: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/50.jpg)
Cardiac arrest occurs in monitored environment with protocols and personnel for rapid initiation
Bridge to maintain oxygenation and circulation till transplant or disease is treatable and self-limiting
![Page 51: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/51.jpg)
Outcomes
![Page 52: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/52.jpg)
![Page 53: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/53.jpg)
Controlled warming after accidental hypothermia
Profound septic shock in children
Massive pulmonary embolism
Prematurity (ECMO as artificial placenta)
Resuscitate “transplantable” organs
- organ preservation after death
![Page 54: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/54.jpg)
Creates a “realistic”, safe and reproducible setting or environment that represents a medical event
![Page 55: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/55.jpg)
![Page 56: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/56.jpg)
ECMO is a complex technique
Organisation and workflow
Teamwork involving many disciplines
Practice actual process of ECMO
![Page 57: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/57.jpg)
Crises management
Leadership
Teamwork & dynamics
Problem solving
Communications
Fixation errors
![Page 58: 3. Prof. Dr. Agnes_ECMO Final](https://reader033.vdocuments.us/reader033/viewer/2022042705/55cf8cf85503462b1390d9ff/html5/thumbnails/58.jpg)
Resource intensive & Expensive
Wide variation in use depending on institute’s philosophy & funding
Patient selection, before irreversible terminal organ damage, who reap the maximum of ECMO